FT-1518

Research use only, not for human use.

FT-1518 is an orally available, selective and potent mTORC1 and mTORC2 inhibitor with anticancer and antitumor activity for cancer research.

FT-1518 is a new generation selective, potent and oral bioavailable mTORC1 and mTORC2 inhibitor, and exhibits antitumor activity.

FT-1518 is a new generation selective, potent and oral bioavailable mTORC1 and mTORC2 inhibitor, and exhibits antitumor activity. FT-1518 displays significant growth inhibitory activity against a large panel of hematologic and solid tumor cell lines with most activities falling into low nanomolar range. FT-1518 cuases potent inhibition of the mTOR pathway biomarkers (mTORC 1 & 2 biomarkers [pAkt(S473) and pS6(S240/244) or p70 S6K), no inhibition of PI3K biomarker [pAkt(T308)] in cells.

FT-1518 exhibits dose-dependent and higher tumor growth inhibition (TGI) in multiple solid tumor xenografts.

——

PI3K/Akt/mTOR signaling

mTOR

mTOR

——

——

1313026-58-2

394.47

C20H26N8O

>98% (HPLC)

In Vitro:?DMSO : 5 mg/mL (12.68 mM; Ultrasonic (<60°C)

N=1C=C(N=CC1N)C2=NC(=NC3=C2N=CN3C(CC)CC)N4CC5OC(C4)CC5

——

(-20℃)

With Ice Pack

≥ 2 years